Tirzepatide CAS:2023788-19-2 Manufacturer Supplier

Tirzepatide was developed as a dual agonist to both GLP-1 and gastric inhibitory polypeptide (GIP) receptors (Frias et al., 2018). Similar to GLP-1, GIP is an incretin hormone that functions to induce insulin secretion.Tirzepatide is in phase 3 development for adults with obesity or overweight with weight-related comorbidity and is currently under regulatory review as a treatment for adults with type 2 diabetes. It is also being studied as a potential treatment for non-alcoholic steatohepatitis (NASH) and heart failure with preserved ejection fraction (HFpEF).

Products Details

Application and Effect

Tirzepatide is used with a proper diet and exercise program to control high blood sugar in people with type 2 diabetes.  Controlling high blood sugar helps prevent kidney damage, blindness,  nerve problems, loss of limbs, and sexual function problems.Tirzepatide has a greater affinity to GIP receptors than to GLP-1 receptors, and this dual agonist behaviour has been shown to produce greater reductions of hyperglycemia compared to a selective GLP-1 receptor agonist. Signaling studies have shown that this is due to tirzepatide mimicking the actions of natural GIP at the GIP receptor. 

Product Sample

Product Packing:

Additional Information:

Composition N.a.
Assay 99%
Appearance White powder
CAS No. 2023788-19-2
Packing 25KG
Shelf Life 2 years
Storage Store in cool and dry area
Certification ISO.

Contact us

Please feel free to give your inquiry in the form below We will reply you in 24 hours